India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Friday the launch of Dapagliflozin Tablets, 5 mg and 10 mg, in the United States.
Lupin's Abbreviated New Drug Application for Dapagliflozin Tablets was approved by US Food and Drug Administration (FDA) as bioequivalent to Farxiga for the indications in the approved labelling.
Farxiga, a brand of biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN), is indicated for the treatment of type 2 diabetes, chronic kidney disease, and symptomatic chronic heart failure.
Rznomics receives FDA RMAT designation for HCC candidate RZ‑001
BioArctic and Eisai report FDA extension of Leqembi Iqlik review
Mezzion reveals pre-IND FDA feedback on udenafil development in ADPKD
Altasciences and Certara form strategic partnership to accelerate early drug development